If you or someone you care for takes Humira — one of the most prescribed drugs for autoimmune conditions that also affect neurological health — you could save between $4,000 and $70,000 per year by switching to a biosimilar. Humira’s list price still hovers around $6,922 for a four-week supply, but biosimilar versions now available in the United States cost as little as $639 per prescription, with some options offering discounts of 80 to 85 percent off the brand-name price. For families already stretched thin by the costs of dementia care or managing chronic inflammatory conditions that overlap with cognitive decline, those savings are not trivial. Since January 2023, when U.S.
market exclusivity finally ended, more than ten biosimilar versions of adalimumab — Humira’s active ingredient — have entered the American market. Yet adoption has been remarkably slow. As of late 2023, fewer than 1,000 of 42,000 eligible patients had actually been switched to a biosimilar. This article breaks down which biosimilars are available, how much each one costs, what “interchangeable” actually means for your pharmacy visit, and why the price you pay can vary by thousands of dollars depending on where you live.
Table of Contents
- How Much Can You Actually Save by Switching From Humira to a Generic Biosimilar?
- Why Did It Take So Long for Humira Biosimilars to Reach the U.S. Market?
- Which Humira Biosimilars Are Available and How Do They Compare?
- How to Talk to Your Doctor About Switching to a Humira Biosimilar
- Why Biosimilar Adoption Has Been Slower Than Expected
- The Broader Market Shift Away From Humira
- What Comes Next for Biosimilar Pricing and Access
- Conclusion
- Frequently Asked Questions
How Much Can You Actually Save by Switching From Humira to a Generic Biosimilar?
The short answer is that savings vary wildly — and that is part of the problem. Among the biosimilars currently on the market, prices range from roughly $639 to $2,655 per prescription, a fourfold spread for what is essentially the same drug. Hadlima, manufactured by Organon and Samsung Bioepis, offers one of the steepest discounts at approximately $1,038 per carton, which represents an 85 percent reduction from Humira’s list price. Hyrimoz from Sandoz comes in at 81 percent off. On the other end, Cyltezo — the first biosimilar designated as interchangeable — carries only a 5 to 7 percent discount, making it barely cheaper than the brand name.
To put this in concrete terms, a patient paying Humira’s list price of roughly $6,922 per month would spend about $83,000 per year. Switching to Hadlima at around $1,038 per month drops that annual cost to approximately $12,456 — a savings of more than $70,000. Even switching to Amjevita, which offers about a 55 percent discount at roughly $3,115 per month, saves around $45,000 annually. For caregivers managing both dementia-related expenses and autoimmune treatment costs, reclaiming even a fraction of that money can mean the difference between affording home care support and going without. Blue Shield of California demonstrated what aggressive negotiation can achieve when it purchased a biosimilar for just $525 per month, compared to Humira’s net price of approximately $2,100 per month. And starting July 1, 2026, MedImpact is launching an unbranded biosimilar at 95 percent below brand-name cost, which could push monthly expenses below $350 for some patients.
Why Did It Take So Long for Humira Biosimilars to Reach the U.S. Market?
Humira’s original patent expired in 2016 — a full seven years before biosimilars actually became available to American patients. The reason for that gap is a legal strategy known as a “patent thicket.” AbbVie filed over 130 secondary patents covering everything from packaging and dosing schedules to injection device design. Each patent created another potential lawsuit for any company trying to bring a competitor to market, effectively building a legal fortress around a drug that had already lost its core intellectual property protection. European patients, by contrast, have had access to Humira biosimilars since October 2018. The difference in timelines is a stark illustration of how the U.S. patent system can be leveraged to extend monopoly pricing far beyond what was originally intended.
Over its lifetime, Humira generated more than $200 billion in revenue for AbbVie, peaking at $22 billion in annual sales in 2021 alone. That revenue stream was protected not by scientific innovation but by legal maneuvering. However, if you assume that this delay is now fully behind us, that is only partially true. While more than ten biosimilars compete on the U.S. market as of 2026, formulary decisions by insurance companies and pharmacy benefit managers still limit which biosimilars are actually accessible to individual patients. Your insurance plan may cover only one or two options, and those may not be the cheapest ones available. Always check your specific formulary before assuming you can access the lowest-cost biosimilar.
Which Humira Biosimilars Are Available and How Do They Compare?
Nine biosimilars have received FDA approval, with eight currently on the market. Amjevita from Amgen was the first to launch, offering discounts of up to 55 percent. Hadlima and Hulio both reach the 85 percent discount mark, making them the most affordable options by list price. Yusimry from Coherus BioSciences comes in at roughly $639 per prescription, which is actually 76 percent less than Amjevita’s price — illustrating that biosimilars compete not just against Humira but against each other. Cyltezo from Boehringer Ingelheim holds a distinction that matters at the pharmacy counter: it was the first biosimilar designated as interchangeable with Humira.
Certain versions of Hadlima have also received interchangeable status. This designation means a pharmacist can substitute these biosimilars for Humira without requiring a new prescription from your doctor, exactly the way a pharmacist can swap a brand-name drug for its generic equivalent. For patients with cognitive impairment or their caregivers who may find it difficult to schedule additional doctor visits, this is a meaningful practical advantage. Pfizer’s Abrilada has been approved but has not yet launched, leaving its pricing and availability uncertain. Other options including Idacio from Fresenius Kabi and Yuflyma from Celltrion are available but have received less attention in formulary negotiations. The sheer number of options is good for long-term competition, but in the short term it creates confusion for patients and prescribers who must navigate an increasingly crowded landscape.
How to Talk to Your Doctor About Switching to a Humira Biosimilar
The first step is understanding that biosimilars are not experimental or inferior. The FDA requires biosimilars to demonstrate that they have no clinically meaningful differences from the reference product in terms of safety, purity, and potency. They are manufactured using living cells, which makes them more complex than traditional generic pills, but the regulatory bar for approval is rigorous. When you bring up the conversation, come prepared with specific numbers. If your current Humira prescription costs $6,922 per month and your insurance copay reflects a percentage of that, switching to Hadlima at $1,038 per month could reduce your copay proportionally.
Ask your doctor whether an interchangeable biosimilar like Cyltezo or an interchangeable version of Hadlima would be appropriate, since those can be substituted at the pharmacy without a separate office visit. If cost is the primary concern and your doctor is open to writing a new prescription, Yusimry at around $639 per script or Hulio at 85 percent off may be worth discussing. The tradeoff to consider is that the cheapest biosimilar may not be on your insurance formulary, while a more expensive one might be covered with a lower copay. A biosimilar listed at $639 does you no good if your plan does not cover it and you would have to pay out of pocket. Your pharmacist and insurance company’s formulary list are essential resources for determining which option actually saves you the most money after coverage is applied.
Why Biosimilar Adoption Has Been Slower Than Expected
Despite the potential for enormous savings, the switch from Humira to biosimilars has been sluggish. As of late 2023, fewer than 1,000 of the 42,000 patients eligible for a switch had actually transitioned. Several factors explain this gap. Pharmacy benefit managers, the intermediaries that negotiate drug prices for insurers, often have rebate arrangements with AbbVie that make Humira financially attractive for the plan even when biosimilars have lower list prices. These behind-the-scenes deals can mean that a cheaper biosimilar never makes it onto a preferred formulary. Geographic variation adds another layer of complexity.
The weighted average cost of adalimumab biosimilars ranges from $2,306 in Michigan to $8,387 in Washington, D.C. — nearly a fourfold difference for the same medication depending on where you fill your prescription. Patients in high-cost regions may find that biosimilar savings are partially eaten up by local pricing dynamics, though they still typically pay less than they would for brand-name Humira. There is also a psychological barrier. Patients who have been stable on Humira for years are understandably reluctant to switch, and some physicians share that caution. For individuals with dementia or cognitive decline who are also managing autoimmune conditions, treatment stability carries particular weight. Any medication change introduces a period of monitoring, and caregivers should discuss with the medical team whether the financial savings justify the transition period, especially for patients who may have difficulty communicating changes in how they feel.
The Broader Market Shift Away From Humira
The financial landscape around Humira has changed dramatically. In 2024, Humira’s U.S. net revenues fell 54.5 percent year over year. Its overall market share dropped to approximately 82 percent by mid-2024, with biosimilars capturing about 18 percent.
In rheumatoid arthritis specifically, Humira’s share fell from 22 percent to 16 percent between the fourth quarter of 2023 and the fourth quarter of 2024, while biosimilar share in that category grew from 3 percent to 10 percent. Perhaps the most telling sign of the shift: Skyrizi, another AbbVie drug, overtook Humira as the company’s top-selling product in the third quarter of 2024, bringing in $3.2 billion compared to Humira’s $2.2 billion. AbbVie itself has moved on. The era of Humira as an untouchable blockbuster is over, and patients who remain on the brand name are increasingly paying a premium for familiarity rather than any clinical advantage.
What Comes Next for Biosimilar Pricing and Access
The most promising development on the horizon is the MedImpact unbranded biosimilar launching July 1, 2026, priced at 95 percent below brand-name cost. If that pricing holds and gains formulary traction, it could set a new floor for adalimumab pricing and pressure other biosimilar manufacturers to cut their prices further. The trajectory in Europe, where biosimilars have been available since 2018 and competition has driven prices steadily downward, suggests that the U.S.
market will follow a similar path — just years behind. For patients and caregivers navigating the intersection of autoimmune disease and cognitive health, the practical advice is straightforward: do not wait for the market to sort itself out. Check your formulary now, ask your doctor about interchangeable options, and compare out-of-pocket costs across the biosimilars available to you. The savings are real, they are substantial, and for many families they are available today.
Conclusion
Humira biosimilars represent one of the most significant opportunities for prescription drug savings in recent memory. With discounts ranging from 55 to 85 percent off Humira’s list price — and new options arriving in 2026 that promise savings of up to 95 percent — patients paying for adalimumab have more affordable alternatives than ever before. The best-case scenario involves annual savings exceeding $70,000, though even modest switches can free up thousands of dollars per year for other aspects of care.
The path to those savings requires some legwork. Check which biosimilars your insurance covers, ask your doctor whether an interchangeable option is appropriate, and compare pricing at your local pharmacy. For caregivers managing both autoimmune treatment and dementia-related expenses, every dollar recovered from inflated drug costs is a dollar that can go toward the care that matters most. The biosimilar market is still maturing, but the window to start saving is open now.
Frequently Asked Questions
Are Humira biosimilars as effective as brand-name Humira?
Yes. The FDA requires biosimilars to demonstrate no clinically meaningful differences from the reference product in safety, purity, and potency. They contain the same active ingredient — adalimumab — and undergo rigorous testing before approval.
Can my pharmacist switch me to a biosimilar without my doctor’s approval?
Only if the biosimilar has been designated as interchangeable. Cyltezo and certain versions of Hadlima carry this designation, allowing pharmacists to substitute them just like a traditional generic. Other biosimilars require a new prescription from your doctor.
Why does the same biosimilar cost different amounts in different states?
Drug pricing in the U.S. is influenced by state regulations, pharmacy benefit manager contracts, wholesaler markups, and local market dynamics. The weighted average cost of adalimumab products ranges from $2,306 in Michigan to $8,387 in Washington, D.C.
Will my copay automatically decrease if I switch to a biosimilar?
Not necessarily. Your copay depends on how your insurance plan classifies the biosimilar on its formulary. In some cases, a biosimilar with a higher list price may have a lower copay than a cheaper one if it sits on a preferred tier. Always check with your insurer before switching.
What is the cheapest Humira biosimilar available right now?
As of early 2026, Yusimry is among the lowest-priced options at approximately $639 per prescription. However, MedImpact is launching an unbranded biosimilar on July 1, 2026, at 95 percent below brand-name cost, which could become the most affordable option available.
Is there any medical reason not to switch from Humira to a biosimilar?
For most patients, switching is safe and straightforward. However, patients who have been stable on Humira for extended periods — particularly those with complex care needs or cognitive impairment — should discuss the transition with their medical team to ensure proper monitoring during the switch.
